Li Ming, Cui Yao, Li Xiqing, Guo Yanwu, Wang Bin, Zhang Jiadong, Xu Jian, Han Shuangyin, Shi Xiwen
Department of Neurosurgery, The People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Department of Tumor, The People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Technol Cancer Res Treat. 2016 Aug;15(4):618-24. doi: 10.1177/1533034615606322. Epub 2015 Aug 27.
The aim of this study was to explore changes in tumor tissues of glioma-bearing rats that underwent argon-helium cryoablation as well as changes in antitumor immunity before and after combined interleukin 12 treatment.
Two hundred sixty Wistar rats were randomly divided into a blank control group, intravenous injection interleukin-12 group, cryotherapy group, and cryotherapy + intravenous injection group. C6 glioma cells proliferated in vitro were implanted subcutaneously on the backs of rats to establish C6 glioma-bearing animal models. Each group underwent the corresponding treatments, and morphological changes in tumor tissues were examined using hematoxylin-eosin staining. CD11c staining was examined using immunohistochemistry, and differences in dendritic cells and T-cell subsets before and after treatment were analyzed using flow cytometry.
The control group showed no statistical changes in terms of tumor tissue morphology and cellular immunity, cryotherapy group, and cryotherapy + intravenous injection group, among which the count for the cryotherapy + intravenous injection group was significantly higher than those of all other groups. In the argon-helium cryotherapy group, tumor cells were damaged and dendritic cell markers were positive. The number of CD11c+ and CD86+ cells increased significantly after the operation as did the cytokine interferon-γ level (P < .01), suggesting a shift toward Th1-type immunity.
Combined treatment of argon-helium cryoablation and interleukin 12 for gliomas not only effectively injured tumor tissues but also boosted immune function and increased antitumor ability. Therefore, this approach is a promising treatment measure for brain gliomas.
本研究旨在探讨荷胶质瘤大鼠经氩氦刀冷冻消融后肿瘤组织的变化以及联合白细胞介素12治疗前后抗肿瘤免疫的变化。
将260只Wistar大鼠随机分为空白对照组、静脉注射白细胞介素-12组、冷冻治疗组和冷冻治疗+静脉注射组。将体外增殖的C6胶质瘤细胞皮下接种于大鼠背部，建立荷C6胶质瘤动物模型。每组进行相应治疗，采用苏木精-伊红染色观察肿瘤组织的形态学变化。采用免疫组织化学检测CD11c染色，采用流式细胞术分析治疗前后树突状细胞和T细胞亚群的差异。
对照组在肿瘤组织形态和细胞免疫方面无统计学变化，冷冻治疗组和冷冻治疗+静脉注射组中，冷冻治疗+静脉注射组的计数显著高于其他所有组。在氩氦刀冷冻治疗组中，肿瘤细胞受损，树突状细胞标志物呈阳性。术后CD11c+和CD86+细胞数量显著增加，细胞因子干扰素-γ水平也显著增加（P<0.01），提示向Th1型免疫转变。
氩氦刀冷冻消融联合白细胞介素12治疗胶质瘤不仅能有效损伤肿瘤组织，还能增强免疫功能，提高抗肿瘤能力。因此，该方法是一种有前景的脑胶质瘤治疗措施。
